Oyster Point Pharma to Participate in the LifeSci Partners Genetic Medicines Summit

PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the LifeSci Partners Genetic Medicines Summit on Tuesday, June 22, 2021, at 2:00 p.m. ET. To access the live webcast, please visit the “Investors and News” section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/. About Oyster Point PharmaOyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases. Investor Contact: Tim McCarthy LifeSci Advisors, LLC (212) 915-2564 [email protected] Media Contact: Sheryl SeapyReal Chemistry (213) 262-9390 [email protected]